KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Elanco Animal Health (ELAN) over the last 8 years, with Sep 2025 value amounting to $505.0 million.

  • Elanco Animal Health's Cash & Equivalents rose 3.06% to $505.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.0 million, marking a year-over-year increase of 3.06%. This contributed to the annual value of $468.0 million for FY2024, which is 32.95% up from last year.
  • Latest data reveals that Elanco Animal Health reported Cash & Equivalents of $505.0 million as of Q3 2025, which was down 6.31% from $539.0 million recorded in Q2 2025.
  • Elanco Animal Health's Cash & Equivalents' 5-year high stood at $638.0 million during Q4 2021, with a 5-year trough of $318.0 million in Q1 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $416.0 million (2024), whereas its average is $423.3 million.
  • In the last 5 years, Elanco Animal Health's Cash & Equivalents slumped by 58.30% in 2021 and then surged by 41.16% in 2025.
  • Quarterly analysis of 5 years shows Elanco Animal Health's Cash & Equivalents stood at $638.0 million in 2021, then slumped by 45.92% to $345.0 million in 2022, then rose by 2.03% to $352.0 million in 2023, then soared by 32.95% to $468.0 million in 2024, then climbed by 3.06% to $505.0 million in 2025.
  • Its Cash & Equivalents stands at $505.0 million for Q3 2025, versus $539.0 million for Q2 2025 and $487.0 million for Q1 2025.